摘要
目的探讨选择性经支气管动脉灌注(BAI)吉西他滨、顺铂结合吉西他滨静脉化疗治疗晚期非小细胞肺癌(NSCLC)的近期疗效;方法随机选择60例经病理证实的原发性晚期NSCLC初治病例行GP方案(吉西他滨1 000 mg/m^2BAI d1,顺铂50 mg/m^2BAI d1;吉西他滨1 000 mg/m^2静脉滴注d8)治疗。结果在可评价的60例患者中,CR 3例,PR 35例,SD 17例,PD 5例,总有效率63%。其中腺癌22例,有效率45%;鳞癌38例,有效率74%(P<0.05);中央型37例,有效率73%;周围型23例,有效率48%(P<0.05)。结论 GP方案经动静脉联合化疗治疗晚期NSCLC的近期效果确切,疗效与肿瘤的解剖部位、病理分型有明显相关性。
Objective To assess the short-term efficacy of bronchial artery infusion （BAI） of Gemcitabine （GEM） plus Cisplatin （DDP） combined with systemic chemotherapy of GEM for advanced non- small cell lung cancer （NSCLC）. Methods A total of 60 patients with pathologically proved primary NSCLC were randomly selected. BAI with GEM （1 000 mg/m2） and DDP （DDP 50 mg/m2） was performed on the first day, and systemic chemotherapy of GEM （1 000 mg/m2） was carried out on the eighth day. The clinical results were analyzed. Results Of the 60 patients, CR, PR, SD and PD were obtained in 3, 35, 17 and 5, respectively, with an overall effective rate of 63%. Twenty-two patients had adenocareinoma and the effective rate of them was 45%. Thirty-eight patients had squamous cell carcinoma and their effective rate was 74%. The difference in the effective rate between the above two pathologic types was significant （P 〈 0.05）. Central type lung cancer was seen in 37 cases, their effective rate was 73%. The peripheral type lung cancer was seen in the remaining 23 patients and the effective rate was 48%. The difference in the effective rate was statistically significant between the central type and the peripheral type （P 〈 0.05）. Conclusion The combination of bronchial artery infusion with systemic chemotherapy by using GP plan is an effective, feasible approach in the treatment of advanced non-small cell lung cancer. The short-term efficacy of the treatment bears a close relationship to the anatomical location and pathological type of the cancer.
出处
《介入放射学杂志》
CSCD
北大核心
2012年第2期119-122,共4页
Journal of Interventional Radiology
关键词
非小细胞性肺癌
吉西他滨
顺铂
近期疗效
non-small cell lung cancer
Gemcitabine
Cisplatin
short-term efficacy
